Alkem Laboratories Limited (BOM:539523)
India
· Delayed Price · Currency is INR | Market Cap | 647.86B |
| Revenue (ttm) | 142.53B |
| Net Income (ttm) | 23.71B |
| Shares Out | n/a |
| EPS (ttm) | 198.31 |
| PE Ratio | 27.32 |
| Forward PE | 27.59 |
| Dividend | 51.00 (0.95%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,575 |
| Average Volume | 4,847 |
| Open | 5,230.05 |
| Previous Close | 5,348.50 |
| Day's Range | 5,230.05 - 5,451.70 |
| 52-Week Range | 4,716.75 - 5,933.00 |
| Beta | n/a |
| RSI | 46.30 |
| Earnings Date | May 26, 2026 |
About Alkem Laboratories
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, r... [Read more]
Financial Performance
In fiscal year 2025, Alkem Laboratories's revenue was 129.65 billion, an increase of 2.34% compared to the previous year's 126.68 billion. Earnings were 21.65 billion, an increase of 20.59%.
Financial StatementsNews
Why are Alkem Laboratories shares falling sharply over 3% today? Explained
Shares of Alkem Laboratories declined more than 3% on April 24, 2026, after the company announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta.…
Alkem Laboratories CEO Vikas Gupta resigns; to step down by June 30
Alkem Laboratories Limited has announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta, who will step down from his role to pursue new professional…
Alkem Laboratories CEO Dr. Vikas Gupta resigns effective June 2026
Alkem Laboratories has announced the resignation of its Chief Executive Officer, Dr. Vikas Gupta. The resignation is effective from 30th June 2026, allowing for a smooth transition of responsibilities...
Alkem Laboratories sets up Dubai free zone subsidiary to drive pharma exports to Africa and South East Asia
Alkem Laboratories Limited has incorporated a wholly owned subsidiary in Dubai, UAE, named Alkem Pharma Trading FZCO, with the specific purpose of expanding pharmaceutical exports to African, South Ea...
Alkem Laboratories establishes wholly owned subsidiary in Dubai
Alkem Laboratories has announced the incorporation of a wholly owned subsidiary, Alkem Pharma Trading FZCO, in Dubai, UAE. The new entity has been established to facilitate the export of Alkem…
Alkem launches A to Z Daily multivitamin with 26 essential nutrients
Alkem Laboratories Ltd. has introduced a new multivitamin supplement, A to Z Daily, aimed at providing comprehensive nutritional support for both body and mind. The supplement is formulated with 26…
Alkem Laboratories increases investment to Rs 1,036 crore for Ujjain facility
Alkem Laboratories has announced an increase in its investment for a greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh. The company has raised its investment from ₹533 crore to ...
Alkem Laboratories establishes wholly owned subsidiary in UAE
Alkem Laboratories has announced the incorporation of a new wholly owned subsidiary, Alkem Pharmaceuticals Scientific Office FZ LLC, in Dubai Healthcare City, UAE. The subsidiary will function as a 'S...
Alkem Laboratories launches semaglutide injection in India at Rs 450 weekly therapy cost
Alkem Laboratories has introduced semaglutide injection in India, targeting type-2 diabetes mellitus and chronic weight management. The therapy is priced at an accessible ₹450 per week, aiming to enha...
Alkem Laboratories receives EU GMP certificate for Daman facility
Alkem Laboratories has been awarded a 'Certificate of GMP Compliance of a Manufacturer' by the Malta Medicines Authority for its manufacturing facility located in Daman, India. This certification is v...
Alkem Laboratories to invest ₹533 crore in new Ujjain manufacturing facility
Alkem Laboratories has announced plans to invest up to ₹533 crore in a new greenfield formulations manufacturing facility in Ujjain, Madhya Pradesh. The investment will be made in a phased…
Alkem Laboratories receives EU GMP certificate for Baddi facility
Alkem Laboratories has been awarded a Certificate of GMP Compliance for its manufacturing facility in Baddi, India, by the German Health Authority. The certificate, which confirms adherence to Good Ma...
Top stocks for trade today, March 9: Tata Power, Dr Reddy’s Laboratories, RITES, KPI Green, Solar Industries and more
Several companies are expected to remain in focus on March 9 following key corporate developments, regulatory updates, project announcements, and business expansion plans. Stocks such as Alkem Laborat...
Pharma sector stocks decline today, March 4: Max Healthcare falls 3.05%, Divi's Lab down 1.85%, Alkem Laboratories drops 1.32%
The Indian pharmaceutical sector experienced a decline on March 4, 2026, amid broader market weakness. Early trading data showed the S&P BSE HEALTHCARE Index at 43,043.3, down 1.6%. The benchmark…
Stocks to buy today, Feb 17: Eicher Motors, Alkem Labs, JK Cement, Tata Steel, Hitachi Energy, LIC Housing Finance, Coforge among brokerage recommendations
Several brokerages have reiterated bullish calls on select large-cap and mid-cap stocks, maintaining positive ratings with revised target prices. Goldman...
Esperion (ESPR) Settles Patent Dispute with Alkem Laboratories
Esperion (ESPR) Settles Patent Dispute with Alkem Laboratories
Top stocks to watch today, Feb 17: Cochin Shipyard, Lupin, Alkem Laboratories, Texmaco Rail and more
Indian equity markets are expected to track stock-specific developments on February 17, with several companies announcing order wins, partnerships, stake...
Alkem Laboratories Ltd (BOM:539523) Q3 2026 Earnings Call Highlights: Strong International ...
Alkem Laboratories Ltd (BOM:539523) Q3 2026 Earnings Call Highlights: Strong International Sales Drive Revenue Growth Amid Profitability Challenges
Q3 2026 Alkem Laboratories Ltd Earnings Call Transcript
Q3 2026 Alkem Laboratories Ltd Earnings Call Transcript
Alkem Laboratories Transcript: Q3 25/26
Q3 FY26 saw 10.7% revenue growth and stable margins, with strong international sales and robust chronic segment performance. Major Medtech acquisition (Occlutech) positions the company for global expansion, targeting 14% CAGR and higher EBITDA margins.
Alkem Laboratories board declares interim dividend of Rs 43 per share for FY26
Alkem Laboratories has announced an interim dividend of ₹43 per equity share with a face value of ₹2 each for...
Alkem Laboratories Q3 Results: Revenue jumps 10.7% YoY to Rs 3,736.82 crore, net profit up 1.9%
Alkem Laboratories reported steady growth in its December 2025 quarter (Q3FY26), with revenue and operating profit improving on a year-on-year...
Earnings To Watch: Alkem Laboratories Ltd (NSE:ALKEM) Reports Q3 2026 Result
Earnings To Watch: Alkem Laboratories Ltd (NSE:ALKEM) Reports Q3 2026 Result
Alkem Laboratories receives GST demand order of Rs 2.35 crore; company plans appeal
Shares of Alkem Laboratories were in focus after the company disclosed that it has received a demand order from the...
Stocks to buy: What's the outlook for Nifty for the week starting January 12, 2026? Check list of top stock recommendations
Stock market recommendations: Sudeep Shah of SBI Securities recommends Alkem Laboratories, and MTAR Technologies as his top stock picks for this week. Here’s his outlook on Nifty, Bank Nifty: